SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-3
Document Type: S-3
Date Filed: 2025-11-26
Accession Number: 0001213900-25-115554
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025115554/ea0266812-s3_synergy.htm

Chunk 0 of 26
Word Count: 1461
Character Count: 9433

Document Content:

As filed with the Securities and Exchange Commission
on November 26, 2025

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM S-3

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Synergy CHC Corp.

(Exact name of registrant as specified in its charter)

Nevada 99-0379440

(State or other jurisdiction of
incorporation or organization) (I.R.S. Employer
Identification Number)

865 Spring Street

Westbrook, ME 04092

(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)

Jack Ross

Chief Executive Officer

c/o Synergy CHC Corp.

865 Spring Street

Westbrook, ME 04092

(Name, address, including zip code, and telephone
number, including area code, of agent for service)

Copies of all communications, including communications
sent to the agent for service, to:

W. David Mannheim

Michael K. Bradshaw, Jr.

Nelson Mullins Riley & Scarborough LLP

301 Hillsborough Street, Suite 1400

Raleigh, NC 27603

Approximate date of commencement of proposed sale
to the public: From time to time after this Registration Statement becomes effective.

If the only securities being registered on this
Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered
only in connection with dividend or interest reinvestment plans, check the following box: ☒

If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant
to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant
to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to
a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities
pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer:	☐	Accelerated filer:	☐

Non-accelerated filer:	☒	Smaller reporting company:	☒

Emerging growth company:	☐

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of Securities Act ☐

The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933 or until the Registration Statement shall become effective on such date as the Commission acting pursuant to said Section
8(a), may determine.

EXPLANATORY NOTE

This registration statement
contains a prospectus and a prospectus supplement:

●	a base prospectus which covers the offering, issuance and sale by the registrant of up to a maximum aggregate offering price of $100 million of the registrant’s common stock, preferred stock, warrants, debt securities, subscription rights and/or units; and

●	a sales agreement prospectus supplement covering the offering, issuance and sale by the registrant
of up to a maximum aggregate offering price of $5.69 million of the registrant’s common stock that may be issued and sold
under a sales agreement, dated November 26, 2025, with Roth Capital Partners, LLC (the “Lead Agent”) and Bancroft
Capital LLC (an “Agent” and together with the Lead Agent, the “Agents”).

The base prospectus immediately
follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in
a prospectus supplement to the base prospectus. The sales agreement prospectus immediately follows the base prospectus. The common stock
that may be offered, issued and sold by the registrant under the sales agreement prospectus is included in the $100 million of securities
that may be offered, issued and sold by the registrant under the base prospectus. Upon termination of the sales agreement with the Agents,
any portion of the $5.69 million included in the sales agreement prospectus supplement that is not sold pursuant to the sales agreement
will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement, and if no shares
are sold under the sales agreement, the full $5.69 million of securities may be sold in other offerings pursuant to the base prospectus.

The information in
this prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities
and Exchange Commission. These securities may not be sold until the registration statement is declared effective. This prospectus is
not an offer to sell these securities, and is not soliciting an offer to buy these securities, nor shall there be any sale of these securities,
in any state or other jurisdiction where such offer, solicitation or sale is not permitted or would be unlawful prior to registration
or qualification under the securities laws of any such jurisdiction.

SUBJECT TO COMPLETION,
DATED NOVEMBER 26, 2025

PROSPECTUS

Synergy CHC Corp.

Common Stock

Preferred Stock

Warrants

Debt Securities

Subscription Rights

Units

We may offer, issue and sell
from time to time together or separately, in one or more offerings, any combination of (i) our common stock, (ii) our preferred stock,
which we may issue in one or more series, (iii) warrants, (iv) senior or subordinated debt securities, (v) subscription rights and (vi)
units. The debt securities may consist of debentures, notes, or other types of debt. The debt securities, preferred stock, warrants and
subscription rights may be convertible into, or exercisable or exchangeable for, common or preferred stock or other securities of ours.
The units may consist of any combination of the securities listed above.

The aggregate public offering
price of the securities that we may offer will not exceed $100 million. We will offer the securities in an amount and on terms that market
conditions will determine at the time of the offering. Our common stock is currently listed on The Nasdaq Capital Market, or Nasdaq, under
the symbol “SNYR.” On November 20, 2025, the last reported sale price of our common stock as quoted on Nasdaq was $2.08 per
share. You are urged to obtain current market quotations of our common stock. We have no preferred stock, warrants, debt securities, subscription
rights or units listed on any market. Each prospectus supplement will indicate if the securities offered thereby will be listed on any
securities exchange.

The aggregate market value
of our outstanding common stock held by non-affiliates is $17.1 million based on 11,251,853 shares of outstanding common stock, of which
6,347,133 shares are held by non-affiliates, and a per share price of $2.69, which was the closing sale price of our common stock as quoted
on the Nasdaq Capital Market on October 22, 2025. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell shares
pursuant to this prospectus with a value of more than one-third of the aggregate market value of our common stock held by non-affiliates
in any 12-month period, so long as the aggregate market value of our common stock held by non-affiliates is less than $75,000,000. During
the 12 calendar months prior to, and including, the date of this prospectus, we have not sold any securities pursuant to General Instruction
I.B.6 of Form S-3.

Investing in our securities
involves risk. You should carefully consider the risks that we refer you to under the section captioned “Risk Factors” in
this prospectus on page 7 before buying our securities.

Should we offer any of the
securities described in this prospectus, we will provide you with the specific terms of the particular securities being offered in supplements
to this prospectus. You should read this prospectus and any supplement, together with additional information described under the headings
“Additional Information” and “Incorporation of Certain Information by Reference” carefully before you invest.
This prospectus may not be used to sell securities unless accompanied by a prospectus supplement.